Recent Developments in Treating Alzheimer’s Disease

Eva Zerovnik1,*, Natasa Kopitar Jerala1 and Robert Layfield2
1Department of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia
2CupKetBip - Center of Excellence for Integrated Approaches in Chemistry and Biology of Proteins, 1000 Ljubljana, Slovenia

Abstract

Early diagnosis and efficient treatment for sporadic Alzheimer’s disease (AD) are urgently needed as the condition becomes an increasing burden within aging societies. We collected recent data on the progress towards effective treatments of AD, from targeting Aβ aggregation, passive immunization with anti-Aβ antibodies, fighting acute and chronic inflammation, modulating autophagy to balancing metals ions. We argue that from successful model studies and pre-clinical trials, insights into the critical pathogenic mechanisms at the molecular and cellular levels are confirmed. They in one way or another seem to support the modified amyloid cascade hypothesis, in which Aβ oligomers are believed to impair intracellular membranes, possibly resulting in mitochondrial and lysosomal dysfunctions that may lead to oxidative stress and impairment in protein clearance by autophagy. In accordance, chronic inflammation due to activation of microglia, is also consistently observed in AD brains.

Keywords: Alzheimer's disease; Aβ oligomers; Autophagy; Cure; Inflammation; Microglia; Mechanisms of neurodegeneration; Prevention; Treatment

Means for Early Diagnosis of AD

At the present time diagnosis of AD is typically obtained when the brains of patients are already severely affected, based on clinical signs of mental decline. Therefore, early diagnosis, possibly at a stage of mild cognitive impairment and selecting those at higher risk to develop the disease, is highly desirable. An early event in AD is over-production of the more toxic amyloid β (Aβ) peptide Aβ42, as opposed to Aβ40. Various imaging techniques enable one to detect and quantify extracellular Aβ plaques in living patients [1] offering a less invasive approach to performing a puncture of cerebral spinal fluid (CSF), in order to analyze the ratio of Aβ40 and Aβ42 peptides. A more convenient approach would be to detect a biomarker in peripheral blood and follow changes in its level upon disease progression. Such an approach has been recently reported by researchers at Rockefeller University who measured the contact system cascade starts with factor XII and bradykinin peptide released downstream. The study showed activation of the inflammation cascade, especially in those patients who demonstrated high levels of Aβ42 in their CSF. Importantly, the Tg6799 mouse model of AD reproduced the findings observed with human blood samples. The authors Zamolodchikov et al. [2] propose that chronic activation of the contact system by Aβ42 results in constant low levels of bradykinin-mediated inflammatory processes in the blood of AD patients (i.e. chronic inflammation). This in turn leads to increased blood–brain barrier permeability and cytokine up-regulation [2]. A review of peripheral biomarkers of AD has been written [3].

Another approach to detect a biomarker in peripheral blood was reported by researchers at the University of Melbourne [4]. They focused on differences in micro-RNAs (miRNA) between AD patients and healthy controls. The miRNA in serum and other biological fluids resides in exosomes. Using next-generation deep sequencing they profiled exosomal miRNA from serum and validated the results by quantitative reverse transcription PCR (qRT-PCR). Additional risk factors for AD including clinical, medical and cognitive factors and amyloid neuroimaging were assessed. An AD-specific 16-miRNA signature was then selected, which together with other risk factors, among them apolipoprotein e4 (APOE e4) allele status, resulted in a sensitivity and specificity of 87% and 77%, respectively, for predicting AD [4].

Trials towards a Successful Treatment for AD

Understanding the molecular and cellular mechanisms of neurodegeneration and neural repair go hand-in-hand with the search for new treatments. The molecular and cellular mechanisms which underlie AD and neurodegenerative diseases in general are essentially a response to protein misfolding and aggregation. As evident from genetic cases the diseases often start with loss of function of the mutated protein, accompanied by toxic effects of protein aggregation. Inflammation, due to innate immunity response, is also important and it is not always clear what comes first [5].

If we start with the modified amyloid cascade hypothesis of AD, it states that Aβ oligomers are responsible for the neuronal and synaptic damage. These oligomers are believed to impair intracellular membranes [6], likely resulting in mitochondrial and lysosomal dysfunctions, which furthermore would lead to oxidative stress and impairment in protein clearance by autophagy, respectively. These events are presumably upstream of hyper phosphorylation and aggregation of Tau. Consequences of aberrant protein aggregation are elevated oxidative stress, impairments in mitochondrial energy levels [7] and autophagic flux with accumulation of auto phagosomes [8].

The soluble Aβ oligomers are thought to be toxic to neurons by the above mentioned amyloid cascade. However, the Aβ peptide

*Corresponding author: Eva Zerovnik, Department of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, 1000 Ljubljana, Slovenia, Tel: 386-147-73753; E-mail: eva.zerovnik@ijs.si

Received January 19, 2016; Accepted March 11, 2016; Published March 18, 2016

Citation: Zerovnik E, Jerala NK, Layfield R (2016) Recent Developments in Treating Alzheimer’s Disease. J Alzheimers Dis Parkinsonism 6: 220. doi: 10.4172/2161-0460.1000220

Copyright: © 2016 Zerovnik E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
also accumulates outside neurons as amyloid-plaques and activates microglia, leading to chronic inflammation.

Decreasing Aβ

In accordance with the modified amyloid cascade hypothesis, many of the new trials in search of treatments for AD are based on reducing the levels of soluble Aβ peptide or clearing the amyloid plaques from the brain blood vessels. An innovative approach was recently applied in a mouse model of AD by the researchers at the University of Queensland, using ultrasound. High frequency sound waves activated the microglia cells, which in turn digested Aβ plaques. As reported by Leinenga and Gotz, memory loss was restored in these mice [9]. As will be described under “Preventive measures” some compounds from plants also reduce amyloid plaques and inhibit intracellular Aβ aggregation.

Immunization

Another means to reduce toxic Aβ oligomers is by immunization. We can differentiate between passive and active immunization, where active means that the body produces it's own antibodies against the peptide of choice. With dangerous species alike Aβ one cannot guarantee that its peripheral injection would not cause seeding effect in the brain leading to more amyloid plaques. As well, people with compromised immune system, which can be the case with AD patients, do not produce sufficient auto-antibodies. Passive immunization with an engineered, preferentially humanized antibodies, is therefore safer, even though, it should be repeated continuously.

Passive immunization trials with antibodies directed against Aβ have been performed for some time, as reviewed by Doris Lambracht-Washington and Roger N. Rosenberg [10]. Several of these had to be abandoned, due to serious side effects, among them aseptic meningoencephalitis [11]. A recent announcement about a possible cure for AD evaluated a high affinity naturally occurring human antibody against Aβ oligomers. These antibodies were isolated from people aged around 100 years, who still were cognitively intact, assuming that they produce powerful auto-antibodies against Aβ peptide. The biological medicine Aducanumab (by Biogen) is a high-affinity monoclonal antibody against Aβ based on the sequence of the auto-antibodies. It recognizes Aβ’s N-terminal structural epitope that is present in the aggregated form of Aβ but absent in monomers. First clinical trials (phase 1b) of passive immunization with Aducanumab were seemingly successful, lowering Aβ plaques in the brain as seen by PET imaging but also improving cognitive performance. However severe side effects were observed such as brain swelling and headaches, especially at the highest, most efficient dose. Medium doses produced less side effects and were still moderately efficient. The trials are being repeated with a wider dose range and more patients.

Another antibody for passive immunization BAN2401: monoclonal antibody directed against Aβ that selectively binds and eliminates Aβ protofibrils is under clinical study. BAN2401 is a promising candidate for Aβ immunotherapy of Alzheimer patients at an early stage [12]. The clinical study (in progress) will evaluate the effect on cognition and biomarkers reflecting the progression of the disease.

Crenuzumab is yet another monoclonal antibody used for passive immunization. It recognizes primarily aggregated Aβ, including oligomeric and fibrillar species and amyloid plaques. In order to avoid side effects such as vasogenic edema, this humanized antibody is prepared on IgG4 backbone, exerting activation of microglia [13].

Decreasing inflammation

Microglia are a unique CNS resident myeloid cell population, derived from primitive myeloid progenitors [14]. When microglial cells become over-activated they induce significant production of cytotoxic molecules such as superoxide [15], NO [16] and tumour necrosis factor-α (TNFα) [17].

In AD microglia are able to bind to soluble Aβ oligomers and Aβ fibrils via cell-surface receptors and this process participates in an inflammatory response. The inflammasome sensor NLRP3 is important for mediating neuroinflammation as it can sense a range of aggregated substances, including Aβ aggregates [18]. Recently several articles described the role of inflammation in AD progression [19,20]. NLRP3-deficient APP/PS1 mice (a mouse model of AD) have decreased deposition of Aβ [19].

A recent study on the role of microglia in an AD animal model was conducted at Stanford University and its success announced early in 2015 [21]. The deterioration in microglial function with age and in AD is driven, in large part, by increased signaling activity of the prostaglandin receptor protein EP2, which resides both on the surface of microglial and neural cells. Activation of the EP2 receptor by prostaglandins E2 or PGE2 leads to inflammation. In more details, the authors Johansson et al. [21] examined peritoneal macrophages of young (4 months) and aged (21 months) C57B6/J mice. When exposed to soluble Aβ oligomers, macrophages from young mice produced a rather modest response, not causing inflammation. In contrast, exposure of macrophages from older mice to Aβ initiated a significant increase in EP2 activity, resulting in inflammation and a reduced amount of Aβ digesting enzymes. A molecule to block the downstream activity of EP2 receptor, i.e. an inhibitor, would be most desirable. In fact non-steroidal anti-inflammatory drugs block two enzymes: COX-1 and COX-2, which produce prostaglandin PGE2 that triggers EP2 action. Non-steroidal anti-inflammatory drugs are widely used in the elderly yet no clear benefits in order to prevent or ameliorate AD symptoms have been observed in patients to date. Some improvements in cognition in animal models were observed for ibuprofen and mefanamic acid [22].

Clinical trials of anti-inflammatory substances (such as aspirin, naproxene…) mostly failed [23]. This seems consistent with recent studies indicating that inflammation is a transient and early phase of AD [5,22]. Inflammasome formation can also result from impaired processes of Beclin-1 dependent autophagy, which is reviewed elsewhere [24].

Metal ions balance

Metal ions balance is critically important for the brain physiology and may be disrupted in AD [25,26]. Cu2+ ion homeostasis was re-established by treating AD mouse model with mild metal chelators, such as clioquinol. Researchers at the University of Melbourne screened substances based on clioquinol backbone to be used as possible chelator drugs. Even though the drug PBT2 reversed memory loss in mice, phase III trial was not performed. Phase I and II clinical trials showed that PBT2 did not improve the burden of amyloid plaques significantly and the trial was stopped after the phase II, as reported by Prana. However recent evidence suggests that the same compound could be efficient to ameliorate cognitive decline accompanying aging [27,28] and even to reverse signs of Parkinson’s disease [29].

Augmenting autophagy

Autophagy is a major route to clear protein aggregates, and may be
Autophagy is induced by several different signaling cascades; of which the best known is mammalian target of rapamycin (mTOR). Multiple mTOR-dependent and mTOR-independent drugs have been tested in AD models. Examples of mTOR-dependent drugs are rapamycin analog temsirolimus (an approved anti-cancer drug) and an mTOR-independent drug is rimendine (anti-hypertension drug). Lithium has a more complicated action and so does sodium-valproate, which is an inhibitor of histone deacetylase.

Inhibition of autophagic flux causes neural death [39]. However it is not certain that enhancing autophagy would be beneficial in all cases of AD. Induction of autophagy seems appropriate at the early stages of AD, whereas later, when extensive accumulation of autophago-lysosomes is observed, it might be counter-productive to enhance autophagic flux especially at more developed phase of the disease, might be contra-productive.

**Table 1: Towards more rational AD treatment; chosen recent treatments.**

1. **Inhibit Aβ oligomerization/ fibrillation:**
   a. antibodies – in clinical studies, Aducunumab, BAN2401, Crenezumab
   b. recruit chaperones, and small heat shock chaperones:
   c. Aβ binding proteins: prion, cystatins, crystallins
   d. Aβ oligomeration inhibitors: polyphenols
   e. disaggregases: chaperones Hsp70 and 104, polyphenols: among them resveratrol and curcumin

2. **Dissolve amyloid plaques:** polyphenol compounds, antibodies, phagocytosis by microglial cells

3. **Augment degradation by autophagy** of the aggregates accumulated in aggresomes and endosomal inclusions: Examples of mTOR-dependent drug is a rapamycin analog temsrolimus (an approved anti-cancer drug) and mTOR-independent drug rimendine (anti-hypertension drug). Lithium has a more complicated action and so does sodium-valproate, which is an inhibitor of histone deacetylase.

4. **Establish metals ions balance:** mild metals chelators – also dissolve the Aβ aggregates, which bind Cu2+ ions; PBT2 by Prana was omitted after clinical trial phase II

5. **Prevent chronic inflammation:** non-steroidal anti-inflammatory drugs, such as ibuprofen and mefenamic acid, block prostaglandin production. Resveratrol and curcumin also exert anti-inflammatory action.

*sometimes enhancing autophagy, especially at more developed phase of the disease, might be contra-productive*

**Preventive Measures**

Because the costs to treat people with AD are enormous and the disease is a significant burden for the relatives and those directly affected, preventive measures are certainly welcome. Physical exercise has been proven as a way to reduce burden of Aβ plaques in patient studies [52,53].

Nutrition is an obvious source of health promoting substances. In a recent survey, the effect of some natural compounds on Aβ aggregation and implications for possible new AD treatments was reviewed [40,41,54] (Table 1). Among the best known plant compounds for their preventive effects on AD are resveratrol and curcumin. It was reported that resveratrol, like many other polyphenols, contributes to Aβ fibril disaggregation [55] and what is even more important to prevent toxicity, inhibits Aβ oligomeration [56]. Similar effects of resveratrol were observed on α-synuclein oligomerization, thus preventing synaptic dysfunction in both AD and PD [57,58].

It was previously shown that resveratrol did not inhibit Aβ production by the two (β and γ) secretases, instead it enhanced proteasome activity [59]. In accordance, the decrease of Aβ was prevented by selective proteasome inhibitors and by siRNA-directed silencing of the proteasome subunit β5 [59]. Curcumin’s inhibitory action on Aβ fibrils formation is also well documented [60-62]. Of note, the same two compounds (resveratrol and curcumin) exert anti-inflammatory and antioxidant actions [63,64].

**Conclusion**

In recent few years several important break troughs in the search for treatment of Alzheimer’s disease (or even a cure) have been made. The aim of this review is, on one hand, to describe these recent developments as illustrated by animal model studies as well as preclinical and clinical trials, and, on the other hand, to highlight the critical pathogenic mechanisms that these studies reveal/confirm.

Undoubtedly, to truly treat AD and similar neurodegenerative
diseases at its source, a better understanding of the molecular and cellular, including glial, neuronal and synaptic mechanisms need to be understood. Here, we argue that modified amyloid cascade hypothesis presents a good basis for such an understanding, proven by success in reducing soluble Aβ oligomers by anti-Aβ oligomers antibodies or aggregation inhibitors (usually also anti-oxidants) derived from plants. Diminishing (dissolving) Aβ plaques and keeping in check accompanying inflammation proved of some help if started early at still mild cognitive impairment. Intensified clearance of the aggregates by autophagy and restoring metals ions balance may also be beneficial in certain (early) stages of disease.

Not at least, better understanding of prion-like templating, seeding and cell to cell spreading of the protein aggregates may be used to stop the routes of spreading [65], which is out of scope of this review.

Funding and Disclosure

This work was funded by the project J7-4050 (E-Z) and the programme P1-0140: proteosilis and its regulation (led by Boris Turk) via the Slovene Research Agency (ARRS).

References

1. Adlard PA, Tran BA, Finkelstein DI, Desmond PM, Johnston LA, et al. (2014) A review of β-amyloid neuroimaging in Alzheimer’s disease. Front Neurosci 8: 327.

2. Zamolodchikov D, Chen ZL, Conti BA, Renne T, Strickland S (2015) Activation of the factor X-driven contact system in Alzheimer’s disease patient and mouse model plasma. Proc Natl Acad Sci U S A 112: 4068-4073.

3. Khan TK, Alkon DL (2015) Peripheral biomarkers of Alzheimer’s disease. J Alzheimers Dis 44: 729-744.

4. Cheng L, Docecke JD, Sharples RA, Villedemagne VL, Fowler CJ, et al. (2015) Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry 20: 1188-1196.

5. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16: 352-372.

6. Bucciantini M, Nosi D, Forzan M, Russo E, Calamai M, et al. (2012) Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB J 26: 818-831.

7. Wang X, Wang W, Li L, Perry G, Lee HG, et al. (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta 1842: 1240-1247.

8. Orr ME, Oddo S (2013) Autophagiclysosomal dysfunction in Alzheimer’s disease. Alzheimers Res Ther 5: 53.

9. Leinenga G, Götz J (2015) Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model. Sci Transl Med 7: 278ra33.

10. Langmacht-Washington D, Rosenberg RN (2013) Advances in the development of vaccines for Alzheimer’s disease. Discov Med 15: 319-326.

11. Orogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology 61: 46-54.

12. Lanfleit L, Möller C, Basun H, Ostwald G, Sehlin D, et al. (2014) Perspectives on future Alzheimer therapies: amyloid-β proteolysis - a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther 6: 16.

13. Adolfsson O, Pilhgren M, Toni N, Varisco Y, Buccarelli AL, et al. (2012) An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32: 9677-9689.

14. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, et al. (2010) Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330: 841-845.

15. Collot CA, Gilbert DL (1987) Production of superoxide anions by a CNS macrophage, the microglio. FEBS Lett 223: 264-288.

16. Moss DW, Bates TE (2001) Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci 13: 529-538.

17. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW (1993) Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150: 2659-2667.

18. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, et al. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865.

19. Heneka MT, Kummer MP, Stutz A, Delekathe A, Schwartz S, et al. (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-678.

20. Heneka MT, Carson MJ, Ei Khoury J, Landrath GE, Broserson F, et al. (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14: 389-405.

21. Johansson JU, Wooding NS, Wang Q, Panchal M, Liang X, et al. (2015) Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease mouse model. J Clin Invest 125: 350-364.

22. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernández J, Campos-Peña V (2013) Inflammatory process in Alzheimer’s Disease. Front Integr Neurosci 7: 59.

23. ADAPT Research Group, Martin BK, Szekely C, Brandt J, Plantadosi S, et al. (2008) Cognitive function over time in the Alzheimer’s disease anti-inflammatory prevention trial (ADAPT) - Results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology 65: 896-905.

24. Saalmann A, Kaarmann K, Kauppinen A (2012) Becn1 interaction controls the crosstalk between apoptosis, autophagy and inflammasome activation: impact on the aging process. Ageing Res Rev 12: 520-534.

25. Adlard PA, Bush AI (2012) Metal chaperones: a holistic approach to the treatment of Alzheimer’s disease. Front Psychiatry 3: 15.

26. Manso Y, Comes G, Hidalgo J, Bush AI, Adlard PA (2011) Copper modulation as a therapy for Alzheimer’s disease? Int J Alzheimer’s Dis 2011: 370345.

27. Adlard PA, Parncutt J, Lal V, James S, Hare D, et al. (2015) Metal chaperones prevent zinc-mediated cognitive decline. Neurobiol Dis 81: 196-202.

28. Adlard PA, Sedjajerta A, Gunawan L, Bray L, Hare D, et al. (2014) A novel approach to rapidly prevent age-related cognitive decline. Aging Cell 13: 351-359.

29. Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, et al. (2015) Clicquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol Dis 81: 169-175.

30. Ciechanover A, Kwon YT (2015) Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med 47: e147.

31. Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, et al. (2007) Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res 1167: 112-117.

32. Shen YF, Tang Y, Zhang XJ, Huang KX, Le WD (2013) Adaptive changes in autophagy after UPS impairment in Parkinson’s disease. Acta Pharmacol Sin 34: 667-673.

33. Friedman LG, Qureshi YH, Yu WH (2015) Promoting autophagic clearance: viable therapeutic targets in Alzheimer’s disease. Neurotherapeutics 12: 94-108.

34. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 16: 46-56.

35. Sarkar S, Rubinsztein DC (2008) Huntington’s disease: degradation of huntingtin by autophagy. FEBS J 275: 4263-4270.

36. Richardson A, Galvan V, Lin AL, Oddo S (2015) How longevity research can lead to therapies for Alzheimer’s disease? Front Psychiatry 3: 15.

37. Polajnar M, Zerovnik E (2011) Impaired autophagy: a link between neurodegenerative diseases and progressive myoclonus epilepsies. Trends Mol Med 17: 203-209.

38. Polajnar M, Zerovnik E (2014) Impaired autophagy: a link between...
neurodegenerative and neuropsychiatric diseases. J Cell Mol Med 18: 1705-1711.

39. Lee KI, Kim MJ, Koh H, Lee JI, Namkoong S, et al. (2015) The anti-hypertensive drug reserpine induces aggralzation of LAMP2 proteins and inhibits autophagic flux. Biochem Biophys Res Commun 462: 402-408.

40. Asthana J, Kapoor S, Mohan R, Panda D (2013) Inhibition of HDAC6 deacteylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J Biol Chem 288: 22156-22256.

41. Hahnen E, Hauke J, Tränkler C, Eulenburg B, et al. (2008) Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 17: 169-184.

42. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, et al. (2006) Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron 51: 703-714.

43. Yang DS, Stavrides P, Mohan HS, Kauhal S, Kumar A, et al. (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits. Brain 134: 258-277.

44. Kaur G, Mohan P, Pawlik M, DeRosa S, Fajiculay J, et al. (2010) Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy. Am J Pathol 177: 2256-2267.

45. Tizon B, Sahoo S, Yu H, Gauthier S, Kumar AR, et al. (2010) Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One 5: e9819.

46. Aad G, Abbott B, Abdallah J, Abdel Khalek S, Abdelalim AA, et al. (2012) Search for the standard model Higgs boson in the diphoton decay channel with 4.9 fb(-1) of pp collision data at √s=7 TeV with ATLAS. Phys Rev Lett 108: 111803.

47. Hamaguchi T, Ono K, Murase A, Yamada M (2009) Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175: 2557-2565.

48. Takahashi S, Ono K, Takamura Y, Mizuochi M, Ikeda T, et al. (2015) Phenolic compounds prevent the oligomerization of ß-synuclein and reduce synaptic toxicity. J Neurochem 134: 943-955.

49. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280: 37377-37382.

50. Caeser I, Jonson M, Nilsson KP, Thor S, Hammarström P (2012) Curcumin promotes ß-amyloid fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS One 7: e31424.

51. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, et al. (2005) Curcumin promotes Aβ fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS One 7: e31424.

52. Coelho FG, Vital TM, Stein AM, Arantes FJ, Rueda AV, et al. (2014) Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer’s disease. J Alzheimers Dis 39: 401-408.

53. Yu F, Bronas UG, Koney S, Nelson NW, Dysken M, et al. (2014) Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer’s disease: study protocol of a randomized controlled trial (The FIT-AD trial). Trials 15: 394.

54. Bu XL, Rao PP, Wang YJ (2015) Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer’s Drug Discovery. Mol Neurobiol .

55. Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, et al. (2010) Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J Biol Chem 285: 24228-24237.

56. Ono K, Li L, Takamura Y, Yoshiike Y, Zhu L, et al. (2012) Phenolic compounds prevent amyloid beta-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem 287: 14631-14643.

57. Hamaguchi T, Ono K, Murase A, Yamada M (2009) Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175: 2557-2565.

58. Takahashi S, Ono K, Takamura Y, Mizuochi M, Ikeda T, et al. (2015) Phenolic compounds prevent the oligomerization of ß-synuclein and reduce synaptic toxicity. J Neurochem 134: 943-955.

59. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280: 37377-37382.

60. Caeser I, Jonson M, Nilsson KP, Thor S, Hammarström P (2012) Curcumin promotes ß-amyloid fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS One 7: e31424.

61. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, et al. (2005) Curcumin promotes Aβ fibrillation and reduces neurotoxicity in transgenic Drosophila. PLoS One 7: e31424.

62. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901.

63. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, et al. (2013) Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 20: 1323-1331.

64. Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105-125.

65. Brettzschneider J, Del Tredici K, Lee VM, Trojanowski QJ (2015) Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 16: 109-120.